Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less dialysis, more kidney? study tests gentler start for kidney failure patients

NCT ID NCT03418181

Disease control Sponsor: East and North Hertfordshire NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether starting haemodialysis with fewer sessions per week (twice instead of the standard three times) can help preserve patients' remaining natural kidney function. New dialysis patients who still have some kidney function are randomly assigned to either standard thrice-weekly dialysis or an incremental approach that adjusts dialysis dose based on their natural kidney function. The goal is to see if this gentler start is feasible and whether it slows the loss of native kidney function, which could improve quality of life and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
incremental haemodialysis (starting with twice-weekly sessions, adjusted based on remaining kidney function)
What this could lead to
If successful, this approach could help new dialysis patients preserve their natural kidney function longer, potentially reducing dietary restrictions and improving survival.
What could go wrong
This is a small feasibility study, not designed to prove effectiveness. The benefits of incremental dialysis are uncertain, and some patients may need more frequent sessions to manage fluid or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Jan 2018

Finished

May 2020

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Advanced renal failure due to underlying primary kidney disease and established as a new starter on haemodialysis within the previous 3 months * Residual Kidney Function likely to permit twice weekly dialysis as defined by interdialytic urea clearance ≥3ml/min/1.73m2 BSA measured routinely as part of standard care * Sufficient understanding of the study procedures and requirements including capacity for explicit agreement to be randomised to standard or incremental HD regimens Exclusion Criteria: * Planned organ transplantation and already on another interventional trial within 3 months from study screening * Anticipated requirement for high-volume ultrafiltration on dialysis (e.g. subjects with daily enteral or parenteral nutrition) * Blood-borne virus positivity * Subjects unable to comply with requirement for monthly interdialytic urine collection. * Pregnancy * Prognosis \<12 months as judged by PI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dialysis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure wild type ABeta2M amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dialysis Kidney failure

Contacts and locations

Locations

  • East and North Hertfordshire NHS Trust (incorporating Mount Vernon Cancer Centre)

    Stevenage, SG1 4AB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.